CL2020003260A1 - Compuestos de naftiridinona sustituidos útiles como activadores de células t - Google Patents
Compuestos de naftiridinona sustituidos útiles como activadores de células tInfo
- Publication number
- CL2020003260A1 CL2020003260A1 CL2020003260A CL2020003260A CL2020003260A1 CL 2020003260 A1 CL2020003260 A1 CL 2020003260A1 CL 2020003260 A CL2020003260 A CL 2020003260A CL 2020003260 A CL2020003260 A CL 2020003260A CL 2020003260 A1 CL2020003260 A1 CL 2020003260A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds useful
- compounds
- cell activators
- naphthyridinone compounds
- substituted naphthyridinone
- Prior art date
Links
- 229940126530 T cell activator Drugs 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 108010062677 Diacylglycerol Kinase Proteins 0.000 abstract 2
- 102100022735 Diacylglycerol kinase alpha Human genes 0.000 abstract 1
- 101710181033 Diacylglycerol kinase alpha Proteins 0.000 abstract 1
- 102100030220 Diacylglycerol kinase zeta Human genes 0.000 abstract 1
- 101710192015 Diacylglycerol kinase zeta Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen los compuestos de la Fórmula (I): o una sal del mismo, en donde: R1, R2, R3, R4, R5, y m son definidos en el presente documento. También se describen métodos para usar tales compuestos para inhibir la actividad de uno o ambos de diacilglicerol quinasa alfa (DGK ?) y diacilglicerol quinasa zeta (DGK?), y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, como el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690439P | 2018-06-27 | 2018-06-27 | |
| US201962840459P | 2019-04-30 | 2019-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003260A1 true CL2020003260A1 (es) | 2021-04-23 |
Family
ID=67439335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003260A CL2020003260A1 (es) | 2018-06-27 | 2020-12-16 | Compuestos de naftiridinona sustituidos útiles como activadores de células t |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10669272B2 (es) |
| EP (1) | EP3814348B9 (es) |
| JP (1) | JP7432532B2 (es) |
| KR (1) | KR20210024586A (es) |
| CN (1) | CN112654621B (es) |
| AU (1) | AU2019291794B2 (es) |
| BR (1) | BR112020026681A2 (es) |
| CA (1) | CA3104654A1 (es) |
| CL (1) | CL2020003260A1 (es) |
| DK (1) | DK3814348T3 (es) |
| ES (1) | ES2960754T3 (es) |
| FI (1) | FI3814348T3 (es) |
| HR (1) | HRP20231253T1 (es) |
| HU (1) | HUE064531T2 (es) |
| IL (1) | IL279728B2 (es) |
| LT (1) | LT3814348T (es) |
| MX (1) | MX2020013817A (es) |
| PE (1) | PE20210469A1 (es) |
| PL (1) | PL3814348T3 (es) |
| PT (1) | PT3814348T (es) |
| RS (1) | RS64641B1 (es) |
| SG (1) | SG11202012972YA (es) |
| SI (1) | SI3814348T1 (es) |
| TW (1) | TW202019924A (es) |
| WO (1) | WO2020006018A1 (es) |
| ZA (1) | ZA202100555B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| WO2021105115A1 (en) | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| BR112022010112A2 (pt) | 2019-11-28 | 2022-09-06 | Bayer Ag | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica |
| US20230064809A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| CA3158532A1 (en) * | 2019-12-19 | 2021-06-24 | Susan Wee | Combinations of dgk inhibitors and checkpoint antagonists |
| KR20220120624A (ko) * | 2019-12-23 | 2022-08-30 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 피페라진 유도체 |
| AR120823A1 (es) * | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| IL294273A (en) * | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted heteroaryl compounds are useful as t-cell activators |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| JP2023522251A (ja) * | 2020-04-24 | 2023-05-29 | バイエル・アクチエンゲゼルシヤフト | 免疫活性化のためのｄｇｋｚｅｔａ阻害剤としての置換アミノチアゾール類 |
| WO2021258010A1 (en) * | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| MX2023006318A (es) | 2020-11-30 | 2023-06-14 | Astellas Pharma Inc | Compuesto de heteroarilcarboxamida. |
| JP2024501207A (ja) | 2020-12-16 | 2024-01-11 | ゴッサマー バイオ サービシズ、インコーポレイテッド | Ｔ細胞活性化剤として有用な化合物 |
| EP4301755A1 (en) | 2021-03-03 | 2024-01-10 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| EP4359389A1 (en) * | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023150186A1 (en) * | 2022-02-01 | 2023-08-10 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| TW202342478A (zh) * | 2022-03-01 | 2023-11-01 | 香港商英矽智能科技知識產權有限公司 | 二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途 |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| BR0312204A (pt) | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| JP2006521400A (ja) | 2003-03-26 | 2006-09-21 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び関連障害の処置のための化合物及びそれらの使用 |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| CA2533626A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| AU2004268941A1 (en) | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| HUE029214T2 (en) | 2005-05-10 | 2017-02-28 | Incyte Holdings Corp | Indolamine-2,3-dioxygenase modulators and methods for their use |
| CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1（pd-l1）的人单克隆抗体 |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110281908A1 (en) | 2008-10-06 | 2011-11-17 | Emory University | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use |
| CN104479018B (zh) | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| US8822462B2 (en) | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
| BR112012004823B1 (pt) | 2009-09-03 | 2021-11-30 | Merck Sharp & Dohme Corp | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| RU2565541C2 (ru) | 2009-12-10 | 2015-10-20 | Ф.Хоффманн-Ля Рош Аг | Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| EP2566517B1 (en) | 2010-05-04 | 2018-10-24 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
| PL2614082T3 (pl) | 2010-09-09 | 2019-02-28 | Pfizer Inc. | Cząsteczki wiążące 4-1BB |
| EP3354640A3 (en) | 2011-04-13 | 2018-10-31 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
| EA036814B9 (ru) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| EP2812355A4 (en) | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
| AR089939A1 (es) | 2012-02-09 | 2014-10-01 | Glenmark Pharmaceuticals Sa | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| BR112014028013A2 (pt) | 2012-05-11 | 2018-02-27 | Five Prime Therapeutics Inc | métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| KR20150047593A (ko) | 2012-08-31 | 2015-05-04 | 파이브 프라임 테라퓨틱스, 인크. | 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| NZ742476A (en) | 2015-12-17 | 2022-09-30 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| CN107216325B (zh) | 2016-03-22 | 2019-06-25 | 上海医药工业研究院 | 萘啶酮类化合物、及其制备方法和应用 |
| WO2017177037A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| LT3558955T (lt) | 2016-12-22 | 2021-11-10 | Amgen Inc. | Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| WO2018134885A1 (ja) | 2017-01-17 | 2018-07-26 | 初実 田中 | 支援奨励システムおよび支援奨励方法 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US20200231551A1 (en) | 2017-06-26 | 2020-07-23 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| JP7312745B2 (ja) | 2018-06-07 | 2023-07-21 | 第一三共株式会社 | アゼチジン誘導体及びそのプロドラッグ |
| SG11202011864XA (en) | 2018-06-27 | 2020-12-30 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing lrrk2 expression |
| MX2020013805A (es) | 2018-06-27 | 2021-03-09 | Oscotec Inc | Derivados de piridopirimidinona para uso como inhibidores de axl. |
| CN112585132A (zh) | 2018-06-27 | 2021-03-30 | 蛋白质平衡治疗股份有限公司 | 蛋白酶体活性增强化合物 |
| MX2020014116A (es) | 2018-06-27 | 2021-06-15 | Reborna Biosciences Inc | Agente profilactico o terapeutico para atrofia muscular espinal. |
| CR20210049A (es) | 2018-06-27 | 2021-07-01 | Biogen Ma Inc | Agentes inhibidores de ask1 |
| CN112689507A (zh) | 2018-06-27 | 2021-04-20 | 普利安特治疗公司 | 具有无支链接头的氨基酸化合物及其使用方法 |
-
2019
- 2019-06-26 PT PT197449234T patent/PT3814348T/pt unknown
- 2019-06-26 RS RS20230895A patent/RS64641B1/sr unknown
- 2019-06-26 HR HRP20231253TT patent/HRP20231253T1/hr unknown
- 2019-06-26 FI FIEP19744923.4T patent/FI3814348T3/fi active
- 2019-06-26 CA CA3104654A patent/CA3104654A1/en active Pending
- 2019-06-26 EP EP19744923.4A patent/EP3814348B9/en active Active
- 2019-06-26 PL PL19744923.4T patent/PL3814348T3/pl unknown
- 2019-06-26 LT LTEPPCT/US2019/039135T patent/LT3814348T/lt unknown
- 2019-06-26 SI SI201930609T patent/SI3814348T1/sl unknown
- 2019-06-26 CN CN201980055715.8A patent/CN112654621B/zh active Active
- 2019-06-26 BR BR112020026681-7A patent/BR112020026681A2/pt unknown
- 2019-06-26 SG SG11202012972YA patent/SG11202012972YA/en unknown
- 2019-06-26 JP JP2020572691A patent/JP7432532B2/ja active Active
- 2019-06-26 MX MX2020013817A patent/MX2020013817A/es unknown
- 2019-06-26 HU HUE19744923A patent/HUE064531T2/hu unknown
- 2019-06-26 KR KR1020217002231A patent/KR20210024586A/ko unknown
- 2019-06-26 DK DK19744923.4T patent/DK3814348T3/da active
- 2019-06-26 WO PCT/US2019/039135 patent/WO2020006018A1/en active Application Filing
- 2019-06-26 ES ES19744923T patent/ES2960754T3/es active Active
- 2019-06-26 US US16/452,679 patent/US10669272B2/en active Active
- 2019-06-26 PE PE2020002111A patent/PE20210469A1/es unknown
- 2019-06-26 AU AU2019291794A patent/AU2019291794B2/en active Active
- 2019-06-27 TW TW108122537A patent/TW202019924A/zh unknown
-
2020
- 2020-04-08 US US16/843,024 patent/US10954238B1/en active Active
- 2020-12-16 CL CL2020003260A patent/CL2020003260A1/es unknown
- 2020-12-23 IL IL279728A patent/IL279728B2/en unknown
-
2021
- 2021-01-26 ZA ZA2021/00555A patent/ZA202100555B/en unknown
- 2021-02-01 US US17/164,009 patent/US11713316B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
| CL2022000485A1 (es) | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t | |
| CL2022001710A1 (es) | Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t | |
| EA202190137A1 (ru) | Нафтиридиноновые соединения для применения в качестве активаторов t-клеток | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| CL2018000293A1 (es) | Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa | |
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| ECSP17002135A (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
| CL2019000512A1 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| BR112022012204A2 (pt) | Compostos de heteroarila substituída úteis como ativadores de célula t | |
| BR112022012179A2 (pt) | Compostos de quinazolina substituída úteis como ativadores de célula t | |
| BR112022012222A2 (pt) | Derivados de piperazina substituídos úteis como ativadores de células t | |
| BR112022012220A2 (pt) | Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| CL2019000662A1 (es) | Inhibidores de dopamina–b–hidroxilasa. | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| DOP2019000119A (es) | Moduladores de ROR gamma (RORy) |